StockWatch
·

BALAJI AMINES LTD.-$ Q2 FY27 Results

BALAMINESQ2 FY27 Results
Filing
Result:Very Good· Market: Down#Broad based#Margin expansion

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue467.602.6%37.3%
Total Income471.982.3%35.8%
Expenditure382.687.7%29.3%
PBT89.3015.9%73.0%
Net Profit67.4713.6%81.8%
OPM21.72%3.69pp4.16pp
NPM14.30%2.63pp3.63pp
EPS20.7610.3%94.6%
View full financials

Chemicals: strong 37.3% revenue growth paired with OPM expansion (17.6%->21.7%) drove 82% core PAT growth, a genuine standout rather than a one-off or base-effect beat.

BALAJI AMINES · Q2 FY-2027 · THE VERDICT

Commodity Tailwind Masks Volume Weakness; New Products the Real Story

Balaji delivered 37% revenue and 82% PAT growth, but both are price-driven, not volume-driven. Sequential PAT fell 13.6% despite revenue growth—a sign of margin compression ahead. The call reveals the honest read: a franchise pivoting to higher-margin specialty chemicals, but earnings are at cyclical peak.

09 Nov 2026 · 6 min read
Q2 Revenue

₹467.6 Cr

+37.3% YoY | +2.6% QoQ

Q2 PAT

₹67.5 Cr

+82% YoY | −13.6% QoQ

EBITDA Margin

22%

vs 19% prior year | Guidance met

H1 Volume

46.1M tons

−14% YoY | Missed +10-15% guidance

Balaji's Q2 looks like a blowout on the headline: 37% revenue, 82% profit growth. But peel back one layer and the tension reveals itself. Volume growth was just 6% quarter-on-quarter and −14% in the first half year-on-year, well below the 10–15% growth promised in the prior call guidance. The entire profit surge was fueled by a commodity price boom—methanol quadrupled from ₹26–30 to ₹61–62, ammonia tripled from ₹45–50 to ₹85–90—that allowed Balaji to take prices. Then in Q2, despite pushing revenue up 2.6% sequentially, PAT fell 13.6%. Sequential margin compression while topline grows is a flashing light: H2 will feel pressure.

Where the profit really came from

EBITDA margin expanded from 19% to 22%, a +300 basis point swing. Management hit the 22–23% guidance. But here is the honest calculation: raw material costs doubled or tripled; that forced Balaji to raise prices faster than customers expected, which lifted volumes only modestly (6% QoQ) but pulled margins up sharply. This is the definition of cyclical earnings leverage. When methanol and ammonia revert to normalized levels—which management itself acknowledged may happen—margin compression will be swift and large.

Management's key claims vs. what holds up

37% YoY revenue growth to ₹472 Cr

Delivered ₹467.6 Cr (35.6% vs ₹348 Cr Q2 FY26)

Supported

82% YoY PAT growth to ₹67 Cr

Delivered ₹67.5 Cr (81% vs ₹37 Cr prior year)

Supported

22–23% EBITDA margin sustainable

Q2 delivered 22%; contingent on commodity prices staying elevated

Partially supported

Volume growth 6% QoQ in healthy demand environment

H1 volume −14% YoY; demand weak despite price hikes

Overstated

DME now >50% utilized; ACN ramping to 1,000+ tons/month

DME commissioned Q1, now 50%+ with 7–8 ISO tanks exported; ACN target 1,000–1,200 tons by year-end

Supported

What changed on this call

  • Multi-year revenue target raised from ₹3,000 Cr (FY28) to ₹3,500–4,000 Cr (FY28–29)

  • DME capacity utilization upgraded: 50%+ now, target 70–90% by FY28 if BPCL approval

  • ACN ramp: current 500–1,000 tons/month demand; target 1,000–1,200 tons by year-end

  • Expansion timelines slipped: Unit-1 brownfield, Unit-2 hydrogen cyanide now year-end target (was July–August)

  • Volume growth guidance implicitly revised downward: H1 delivered −14% YoY vs +10–15% prior commitment

The bull-bear ledger

  • 82% PAT growth YoY demonstrates operational leverage to commodity cycles

  • 22% EBITDA margin achieved despite −14% H1 volume decline shows pricing power

  • Three new specialty products (DME, ACN, NMM) entering commercialization; high-margin runway

  • Specialty Chemicals (BSCL) expansion on track; ₹30–40 Cr revenue by FY28 incremental

  • Strong cash generation (₹54.5 Cr H1 OCF) funding ₹200+ Cr capex with no capex stress

  • Revenue growth entirely price-driven; volume −14% H1 YoY indicates weak underlying demand

  • Sequential PAT fell 13.6% despite 2.6% revenue growth; margin compression starting in H2

  • Commodity price dependency extreme; guidance assumes prices stay 2–3x normal levels

  • FY28–29 target ₹3,500–4,000 Cr contingent on multiple assumptions (prices, volumes, execution)

  • New product revenue contribution Q2 negligible (exports/samples only); FY28 ramp uncertain

  • FII ownership down 183 basis points YoY (5.0% → 3.17%); institutional conviction waning

Earnings quality: where the pressure lies

Key risks ranked by severity to a holder

Commodity price normalization

High

If methanol/ammonia revert to historical ₹26–30/₹45–50 levels, EBITDA margin compresses from 22% to 18–20% (−200–400 bps). ₹3,500–4,000 Cr target becomes unachievable without volume recovery; earnings downside material.

Volume recovery stalled

High

H1 −14% YoY despite price surge indicates weak end-market demand (pharma, agro, paint). Balaji missed 10–15% growth from prior guidance; no evidence demand has inflected positively. FY28 volume ramp needed to justify guidance.

New product adoption delays

Medium

DME, ACN, NMM revenue contribution Q2 negligible (exports/samples only). BPCL approval for LPG blending, Road Tanker certification 3–4 weeks away; customer trials ongoing. If adoption slower than expected, FY28 revenue unachievable.

Expansion execution slippage

Medium

Unit-1 brownfield, Unit-2 hydrogen cyanide already pushed from July–August to year-end. Plant shutdown needed during commissioning (10–15 days per cycle). Further delays compress H2 FY27 revenue and push new capacity monetization to FY28.

Sequential margin compression confirmed

Medium

PAT −13.6% QoQ despite +2.6% revenue growth shows margins weakening in Q2 already. If this trend continues into H2, full-year EBITDA margin may miss 22–23% guidance.

How the street is positioned

Balaji's stock has sold off sharply: down 65.62% from its all-time high of ₹5,223.55, now trading at ₹1,796.1. It is below both the 20-day average (₹1,877.6) and the 50-day average (₹2,092.41), though above the 200-day average (₹1,737.19). The RSI of 38.6 is neutral—not oversold. The bigger signal is in ownership: FII holding have dropped 183 basis points year-on-year from 5.0% to 3.17%. This isn't panic selling; it's a quiet reallocation. DII and promoters are steady, but foreign money is reducing conviction. Volume is normal, suggesting no capitulation. The 52-week low was ₹968.1 (now +85.5% above that), and the high ₹2,629.2 (now −31.6% below). The stock's 65% drawdown from ATH is severe, but the valuation remains in the middle of its recent range—not an extreme reversal, not a screaming buy either. The sell-off has been gradual, matching disappointments on volume growth and timeline slips. The institutional trim reflects the same tension the call reveals: strong reported earnings masking weak organic demand and commodity cycle peaks.

What to watch next
  • 1 · Q3 FY27 volume and ACN ramp trajectory

    The key to the FY28–29 target is volume recovery. Watch for: Acetonitrile reaching 1,000+ tons/month by year-end; DME utilization holding above 50%; ACN demand from battery electrolyte OEMs. If volumes keep declining, the ₹3,500–4,000 Cr target is fantasy. If they stabilize or recover, the bull case gets legs.

  • 2 · Commodity price normalization and margin guidance

    Methanol and ammonia pricing is the lever. If prices stay at ₹61–62 and ₹85–90, Balaji holds 22%+ margins. If they revert toward ₹26–30 and ₹45–50 (even 50% mean reversion), margins compress 200–300 basis points. Q3 earnings will signal whether margin pressure from Q2 extends. Guided range is 22–23%; miss that and FY28 guidance collapses.

  • 3 · Expansion execution and year-end commissioning

    Unit-1 brownfield, Unit-2 hydrogen cyanide, Acetonitrile expansion all targeted for year-end. Any delay pushes new capacity revenue into FY28. Successful on-time completion validates execution confidence and unlocks 70–90% utilization by FY28, which is a material earnings driver.

Balaji Amines delivered a solid Q2 operationally—management executed well, costs stayed controlled, margins held firm. But the quarter is a reminder of how cyclical this business is. Reported earnings jump because raw material costs spike, forcing price hikes that flow through to profit. When commodity cycles normalize, earnings will contract just as quickly. The real story is the new product pipeline (DME, ACN, NMM) and the specialty chemicals expansion. If those scale and volume recovers, the long-term thesis holds. If volume keeps falling and commodities revert, the ₹3,500–4,000 Cr target is a mirage.

The stock's 65% drawdown from peak is not unjustified. FII inflows have reversed. The steady message from here is: watch volume, watch commodity prices, watch capex execution. Until one of those inflects positively, hold and wait. The number to track is H1 volume trajectory: if H2 shows recovery toward 10–15% YoY growth, the bull case gains traction. If it stays negative, the near-term stays pressured, and the FY28–29 aspiration becomes a question, not a forecast.

Informational and educational content only. Not investment advice.